A

Agenus

AGEN

5.99000
USD
-0.05
(-0.83%)
مفتوح الان
حجم التداول
4,501
الربح لكل سهم
0
العائد الربحي
0
P/E
-0
حجم السوق
96,642,296
أصول ذات صلة
A
ADVM
0.09000
(1.21%)
7.53000 USD
A
ARWR
-1.160
(-4.06%)
27.410 USD
C
CYTK
-1.150
(-1.95%)
57.910 USD
K
KPTI
-0.06290
(-6.37%)
0.92380 USD
O
OCUL
-0.40000
(-4.72%)
8.07000 USD
P
PRTK
0.03500
(1.59%)
2.23000 USD
V
VTGN
-0.04000
(-1.18%)
3.36000 USD
X
XNCR
-0.600
(-2.93%)
19.880 USD
الأخبار المقالات

العنوان: Agenus

القطاع: Healthcare
الصناعة: Biotechnology
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).